• Call :+91-11-2688 8181 / 46152728
  • English
  • French
  • Spanish
Anti-Cyclic Citrullinated Peptide (CCP) Anti-CCP Elisa Test Kit
Pack Size :
96 Well
` 17500/-
Our Price :
` 13650/-
Check delivery estimate for your pincode


Pack Size : 96 Well

Package Kit Components :

  • Microwells coated
  • Conjugate
  • Substrate
  • Stop Solution           
  • Wash Buffer
  • Sample Diluent
  • Calibrators
  • Control
  • Positive Control
  • Negative Control
  • Technical Insert

Usage : The Anti-CCP test is a semi-quantitative/qualitative enzyme-linked Immunosorbent assay (ELISA) for the detection of the IgG class of auto antibodies specific to cyclic citrullinated peptide (CCP) in human serum (including Serum Separator Tubes) or plasma (EDTA, lithium heparin, or sodium citrate).  Detection of anti-CCP antibodies is used as an aid in the diagnosis of Rheumatoid Arthritis (RA), and should be used in conjunction with other clinical information.  Autoantibody levels represent one parameter in a multi-criterion diagnostic process, encompassing both clinical and laboratory-based assessments. 

Description : Rheumatoid Arthritis (RA) is a common, systemic autoimmune disease affecting 0.5- 1.0% of the adult population. RA is characterised by chronic inflammation of the synovium which can lead to progressive joint destruction and in many cases lead to disability and reduction of quality of life.1 It is generally accepted that early intervention is vital in preventing irreversible joint damage and it is therefore important to diagnose RA as early in the disease course as possible.2,3 The diagnosis of RA is primarily based on clinical, radiological and immunological features. The most frequent serological test is the measurement of rheumatoid factor (RF).4 Although the RF test has good sensitivity, it is not specific for RA, as it is often present in healthy individuals and patients with other rheumatic or inflammatory diseases, autoimmune diseases or chronic infections.5 For several years, it has been recognised that antibodies to anti-perinuclear factor (APF) and keratin (AKA) are highly specific for RA. It was subsequently reported that both these antibodies reacted with native filaggrin and now are referred to as anti-filaggrin antibodies (AFA).6,7,8 Recent evidence has shown that all these antibodies are directed to citrulline containing epitopes.9 Citrulline is a non-standard amino acid, as it is not incorporated into proteins during protein synthesis. It can however be generated via post-transitional modification of arginine residues by the enzyme peptidylarginine deiminase (PAD).10 In 1998, Schellekens and colleagues reported that auto antibodies reactive with linear synthetic peptides containing citrulline were highly specific for RA in an ELISA based assay.11 Subsequent studies demonstrated that cyclic variants of these linear peptides, termed cyclic citrullinated peptides (CCP) were as specific for RA but with a higher sensitivity than the linear peptides.12 In an effort to further improve the sensitivity of the CCP test, a dedicated library of citrulline-containing peptides was screened with RA sera and a new set of peptides (CCP2) was discovered which gave superior performance compared to the CCP1 test.13 Over the last few years many published reports have confirmed the diagnostic performance of the CCP2 test.14 Anti-CCP antibodies, which are also often termed as anti-citrullinated protein/peptide antibodies

(ACPA’s), have been found to be present very early in the disease, often with the absence of clinical symptoms and many reports indicate that elevated levels of anti-CCP antibodies can predict the development of erosive disease.15,16,17,18,19,20 These findings suggest an important role for cyclic citrullinated peptides in the diagnosis of RA at an early stage of the disease course. 

In 2010 the ACR / EULAR Rheumatoid Arthritis Classification Criteria were published and replaced the "old" ACR criteria of 1987 which were widely considered not to be suitable for the early diagnosis of RA. The revised classification criteria, jointly published by the American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) recommend a point scoring system of between 0 and 10. The new classification criteria are to be applied to every individual presenting with definitive synovitis (undifferentiated inflammatory Arthritis). The four additional criteria were number of joints involved, serologic abnormality, acute-phase response and duration of symptoms in the involved joints. For the first time the serologic criteria included measurement of ACPAs, such as anti-CCP, as well as some definition of a low positive and high positive serology result.21 

The  Anti-CCP assay is an ELISA based on the detection of auto antibodies in human serum or plasma towards a synthetic cyclic peptide containing modified arginine residues (CCP2 peptides). The test provides an additional tool in the diagnosis of patients with RA.